Company profile: Cellectar Biosciences
1.1 - Company Overview
Company description
- Provider of radiopharmaceutical cancer therapies and diagnostics, designing phospholipid drug conjugates that target tumor cells to detect, treat, and monitor cancers. Lead candidate iopofosine I 131 is in Phase 2/1 studies. Pipeline includes CLR 1900 cytotoxic compounds and collaborative PDC programs (CLR 2000, CLR 12120) with Avicenna and Orano Med, plus new PDCs with IntoCell and LegoChemBio.
Products and services
- Iopofosine I 131: Clinical‑stage small‑molecule Phospholipid Drug Conjugate delivering iodine‑131 selectively to cancer cells while minimizing healthy cell exposure, in Phase 1/2 for Waldenström’s macroglobulinemia and pediatric cancers
- New PDCs with LegoChemBio: Custom‑engineered three new small‑molecule PDCs combining Cellectar’s PLE targeting technology with LegoChemBio’s drug conjugate linker‑toxin platform to attack solid tumors with precise payload delivery
- New PDCs with IntoCell: Modular PDCs integrating IntoCell’s novel linker chemistry with Cellectar’s targeting platform, advancing to IND‑enabling studies for development of new phospholipid drug conjugates.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cellectar Biosciences
Travanti Pharma
HQ: United States
Website
- Description: Provider of innovative drug delivery platforms that improve the safety, compliance, effectiveness, and ease of administration of medications delivered into the body; designs, develops, and markets these platforms to enhance medication delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Travanti Pharma company profile →
Nurse Assist
HQ: United States
Website
- Description: Provider of medical devices and USP sterile solutions, including prefilled saline syringes for IV flushing, sterile water and normal saline for irrigation and respiratory care, and sterile saline wound flush for moistening, debriding, and cleaning wounds, helping reduce contamination, medication errors, and needlestick injuries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nurse Assist company profile →
Medical International Technology
HQ: Canada
Website
- Description: Provider of needle-free jet injectors for human and animal vaccinations, developing, marketing, and distributing these devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medical International Technology company profile →
Qnovia
HQ: United States
Website
- Description: Provider of medtech and pharmaceutical drug-delivery solutions, including RespiRx, an inhalable prescription nicotine replacement therapy for smoking cessation; an inhaled drug delivery platform that optimizes and tracks dosing to improve efficacy and compliance; and a portable, orientation-agnostic vibrating mesh nebulizer with a digital metered dose interface, Bluetooth-enabled app, and a zero-maintenance disposable cartridge.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Qnovia company profile →
Mercator MedSystems
HQ: United States
Website
- Description: Provider of site-specific delivery devices for the treatment of vascular, oncologic, and regenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mercator MedSystems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cellectar Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cellectar Biosciences
2.2 - Growth funds investing in similar companies to Cellectar Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cellectar Biosciences
4.2 - Public trading comparable groups for Cellectar Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →